{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:43:22Z","timestamp":1791819802810,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bone.2017.08.003","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T23:15:28Z","timestamp":1501974928000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":473,"special_numbering":"C","title":["Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS"],"prefix":"10.1016","volume":"105","author":[{"given":"Elena","family":"Tsourdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9rengere","family":"Aubry-Rozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Fink","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Gua\u00f1abens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carola","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2017.08.003_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2017.08.003_bb0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbm.a.31599","article-title":"Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro","volume":"85","author":"Henneman","year":"2008","journal-title":"J Biomed Mater Res A"},{"issue":"24","key":"10.1016\/j.bone.2017.08.003_bb0015","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bone.2017.08.003_bb0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effects of 3 versus 6years of zoledronic acid treatment of osteoporosis: a randomised extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.bone.2017.08.003_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.bone.2017.08.003_bb0030","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","article-title":"Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK. National Osteoporosis Guideline Group (NOGG) update 2013","volume":"75","author":"Compston","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2017.08.003_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","article-title":"Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement","volume":"101","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"issue":"8","key":"10.1016\/j.bone.2017.08.003_bb0040","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.bone.2017.08.003_bb0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.bone.2017.08.003_bb0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s001980170107","article-title":"Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women","volume":"12","author":"Tremollieres","year":"2001","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.bone.2017.08.003_bb0055","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bone.2009.10.043","article-title":"The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women","volume":"46","author":"Naylor","year":"2014","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2017.08.003_bb0060","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2017.08.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.bone.2017.08.003_bb0070","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.bone.2017.08.003_bb0075","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00198-016-3886-y","article-title":"Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2years","volume":"28","author":"Modi","year":"2017","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.bone.2017.08.003_bb0080","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.bone.2017.08.003_bb0085","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2017.08.003_bb0090","article-title":"Rebound-associated bone loss after non-renewal of long-term denosumab treatment offsets 10-year gains at the total hip within 12months","volume":"31","author":"Popp","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2017.08.003_bb0095","article-title":"Significant bone loss after stopping denosumab treatment","volume":"31","author":"Zanchetta","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.bone.2017.08.003_bb0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.bone.2017.08.003_bb0105","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2017.08.003_bb0110","article-title":"Bone michroarchitecture after discontinuation of denosumab in postmenopausal women with low bone mass","volume":"31","author":"Seeman","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.bone.2017.08.003_bb0115","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","article-title":"Hypercalcemia after discontinuation of long-term denosumab treatment","volume":"27","author":"Koldkj\u00e6r S\u00f8lling","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.bone.2017.08.003_bb0120","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.bone.2017.08.003_bb0125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bone.2017.08.003_bb0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bone.2016.08.010","article-title":"The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: THE TRIO Study","volume":"92","author":"Gossiel","year":"2016","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2017.08.003_bb0135","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of Denosumab in osteoporosis every 6months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.bone.2017.08.003_bb0140","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.bone.2017.08.003_bb0145","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.bone.2017.08.003_bb0150","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.bone.2017.08.003_bb0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical case report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.bone.2017.08.003_bb0160","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.bone.2017.08.003_bb0165","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2017.08.003_bb0170","article-title":"Fracture risk after discontinuation of denosumab","volume":"31","author":"Yusuf","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2017.08.003_bb0175","article-title":"Discontinuation of Denosumab and associated fracture incidence: analysis from FREEDOM and its extension","volume":"31","author":"Brown","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2017.08.003_bb0180","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.bone.2017.08.003_bb0185","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2017.08.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2017.08.003_bb0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-Up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.08.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","author":"Lehmann","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.bone.2017.08.003_bb0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.bone.2017.08.003_bb0210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11914-015-0295-7","article-title":"How long to treat with denosumab","volume":"13","author":"Costa","year":"2016","journal-title":"Curr Osteoporos Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2017.08.003_bb0215","article-title":"Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8years of denosumab treatment","volume":"31","author":"Ferrari","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"9999","key":"10.1016\/j.bone.2017.08.003_bb0220","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2007","journal-title":"Lancet"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217302673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217302673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T02:29:27Z","timestamp":1569983367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328217302673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":44,"alternative-id":["S8756328217302673"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}